Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

Do you refer patients to cardiology if they have no history of cardiac disease but will be receiving XRT with high mean doses to the heart?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Pennsylvania Health System

Great question! Yes, we are starting to refer patients to cardiology who have Stage III NSCLC or LS-SCLC and are receiving high-dose radiation therapy. Trying to tease out whether its heart dose or central tumor location, or some combination of the two, that confers a poorer prognosis is challenging...

How do you decide treatment volumes for radiotherapy for bilateral gynecomastia secondary to bicalutamide therapy?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · VA New Jersey Healthcare System - East Orange campus.

I recall treating more of these cases in prostate cancer patients in the earlier period of my career when DES and flutamide was used more often. And I don't recall having to re-treat anyone. We did both therapeutic and prophylactic RT -> with the latter we/some use 8-10Gy x1(http://www.nice.org.uk/c...

In a patient with Waldenstrom's macroglobulinemia doing well and feeling better on ibrutinib & rituximab, but with a rising IgM, do you switch treatment or continue?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Moffitt Cancer Center

A lot depends on the pace of increase of the IgM and the line of therapy. If the pace is rapid, I would think about changing therapy. If the pace of increase is small and the patient is asymptomatic, you could continue a little longer. If planning to changing therapy, it may be reasonable to restage...

When considering post mastectomy radiation, do your recommendations change for a biopsy proven positive intramammary node in the axillary tail (prior to neoadjuvant chemotherapy) vs. positive axillary node?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Data on intramammary nodal disease suggest that it has worse outcome than node negative disease and these pts at increased risk of axillary involvement I do take that as one of adverse factors in deciding PMRT after NACT in these pts but if they have BCT done then don't change target in itself based...

How would you treat a patient with locally and distant recurrent rectal cancer who has previously received chemoradiation but now presents with pain and bleeding from the site of local recurrence?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan-Kettering Cancer Center

Generally we like to see a 1 year interval between courses of radiation. We give 39Gy in 26 fx BID with a 3D conformal technique. The cumulative BED should be <100 or so. We use a 3 cm margin cranial an caudal on the GTV and include the presacral space. We give concurrent capecitabine.

How does breast cancer histology affect your decision whether to omit radiation?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

More than histology grade ( grade 3) influences whether to omit RT or not .

Are connective tissue disorders a contraindication to breast radiation?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Allegheny Health Network, Pittsburgh

I don't have any personal experience treating Ehlers Danlos syndrome. A case report has been recently published: https://www.ncbi.nlm.nih.gov/pubmed/28727212

Do you offer consolidation thoracic radiation after atezolizumab, carboplatin, and etoposide for extensive stage small cell lung cancer?

2
3 Answers

Mednet Member
Mednet Member
Medical Oncology · Indiana University School of Medicine

I have not had the opportunity to treat a patient yet with carboplatin plus etoposide plus atezolizumab. This regimen is not yet FDA approved (as of 2/18/19) to treat patients with extensive stage small cell lung cancer. However, when it becomes FDA approved, I will plan on offering this regimen to ...

Are there any known issues related to radiation in the setting of vitiligo?

3
6 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Maryland

I have treated several breast cancer patients with vitiligo with both photon and proton radiation therapy. In Caucasian people with the disease, I have found that the areas of vitiligo either stay hypopigmented (no pigment change) or I have had a handful of patients turn bright red in the areas of h...

How would you manage simultaneous muscle invasive bladder cancer and intermediate or high risk prostate cancer in a patient who refuses surgery?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Virginia Commonwealth University Medical Center

When I'm faced with a situation like this, with 2 concurrent pelvic malignancies, I like to think about how I would manage each one independent of the other and then try to design a plan that incorporates management principals of both diseases. You also have to consider how treating both concurrentl...